Retatrutide Phase 3 Obesity Trial: What TRIUMPH-1 Shows

The retatrutide phase 3 obesity trial, TRIUMPH-1, found that adults with obesity or overweight without diabetes lost an average of 17.6% to 25.0% of body weight after 80 weeks, compared with 3.9% with placebo. The study also reported improvements in knee osteoarthritis pain and obstructive sleep apnea measures. Retatrutide, also called LY3437943, remains investigational as of October 3, 2026. Because the study did not directly compare retatrutide with approved medicines, it cannot establish superiority over them.

TRIUMPH-1 was published on September 29, 2026, in the New England Journal of Medicine. The peer-reviewed report describes a phase 3, double-blind, placebo-controlled study of 2,339 adults. Participants received once-weekly retatrutide at 4 mg, 9 mg, or 12 mg, or matched placebo, for 80 weeks. Eli Lilly funded the study and is developing the investigational molecule.

These findings provide larger and longer phase 3 evidence than earlier retatrutide studies. The trial also examined outcomes beyond body weight. Prespecified subgroups assessed knee osteoarthritis pain and obstructive sleep apnea, two conditions that commonly occur alongside obesity. Important questions remain, including long-term safety, cardiovascular outcomes, and direct comparisons with other obesity medicines.

What the retatrutide phase 3 obesity trial tested

Retatrutide is designed to activate three hormone receptors in one molecule: the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. This is why it is often called a triple agonist.

GLP-1 signaling can affect appetite and stomach emptying. GIP signaling is involved in insulin regulation and energy handling. Glucagon signaling can affect energy expenditure and liver metabolism. Researchers are studying whether targeting all three pathways produces effects that differ from medicines targeting one or two receptors.

This design differs from <a href="https://glp1place.com/tools/compound/semaglutide/”>semaglutide, which primarily activates the GLP-1 receptor, and tirzepatide, which activates GLP-1 and GIP receptors. GLP1Place has separately explained these pathway differences in its comparison of retatrutide, tirzepatide, and semaglutide mechanisms.

TRIUMPH-1 enrolled adults with obesity or overweight and at least one weight-related health condition. Participants did not have diabetes. The protocol also included two prespecified subgroups:

• 574 participants with knee osteoarthritis, assessed with the Western Ontario and McMaster Universities Osteoarthritis Index, known as WOMAC.
• 243 participants with obstructive sleep apnea, assessed with the apnea-hypopnea index, known as AHI.

WOMAC is a questionnaire that measures pain, stiffness, and physical function. Higher scores indicate worse symptoms. AHI counts breathing interruptions or reductions per hour of sleep. These measures do not capture every effect of osteoarthritis or sleep apnea, but they are established tools for assessing changes in symptoms and breathing events during a clinical trial.

The report used more than one statistical approach. For body weight, the primary analysis used a treatment-regimen estimand. In simple terms, this estimates the effect of the assigned treatment strategy. For knee pain and sleep apnea, investigators also reported hybrid-estimand and intention-to-treat analyses. These approaches answer related, but not identical, questions, so the results require careful interpretation.

Retatrutide phase 3 obesity trial weight-loss results

Weight loss at week 80 increased with the studied retatrutide dose. According to the published TRIUMPH-1 report, all three retatrutide groups had greater average weight reduction than the placebo group under the treatment-regimen analysis.

The 9 mg and 12 mg comparisons were the primary weight comparisons, and both had P values below 0.001. These figures are group averages from a defined statistical analysis. They do not mean every participant lost the same percentage of body weight. Individual responses varied, and some participants discontinued treatment.

The 3.9% average reduction in the placebo group also matters. People in both groups participated in a closely monitored study and received dietary and activity counseling. Those conditions can affect weight independently of the investigational medicine. The main efficacy question is therefore the difference between each retatrutide group and placebo, not just the raw percentage in one group.

It may be tempting to compare the 25.0% average directly with results from other obesity-drug trials, but those comparisons have limits. Trials can differ in who enrolls, how long they last, dose-escalation methods, lifestyle support, handling of missing data, and the statistical estimand used. A randomized head-to-head trial is needed to determine whether one medicine outperforms another in a comparable population.

What an 80-week result can and cannot show

Eighty weeks is a meaningful duration for obesity research. It provides more information than a short dose-finding study about sustained treatment effects and common adverse events. However, it does not answer every long-term question. This study alone cannot establish what happens after several years of exposure, after treatment ends, or whether the observed weight changes lead to fewer cardiovascular events.

The findings also apply to the trial population: adults with obesity or overweight, at least one weight-related condition, and no diabetes. Results may not apply in the same way to people with different medical histories, age groups, disease severity, or characteristics excluded by the study criteria.

What the knee osteoarthritis findings show

Excess body weight can place added mechanical stress on knee joints. It is also linked with inflammatory and metabolic changes that may affect osteoarthritis symptoms. TRIUMPH-1 included a knee osteoarthritis subgroup and measured pain with the WOMAC pain scale.

Under the hybrid-treatment estimand, WOMAC pain scores changed by approximately -3.2 points with 4 mg retatrutide, -3.5 points with 9 mg, and -3.6 points with 12 mg. The placebo group improved by 1.9 points. The estimated differences versus placebo were -1.6 points for 9 mg and -1.8 points for 12 mg, both statistically significant.

The intention-to-treat analysis also favored retatrutide. Pain scores changed by -3.4, -3.9, and -4.1 points across the three retatrutide dose groups, compared with -2.5 points with placebo. The differences for the 9 mg and 12 mg groups remained statistically significant.

These results indicate that participants in this subgroup reported greater improvement in knee pain than placebo recipients. They do not establish retatrutide as a direct joint-repair treatment. TRIUMPH-1 was not designed to show reversal of cartilage damage, repair of joint structures, or benefit independent of weight change. Reduced mechanical load, altered inflammation, improved mobility, and other factors could all contribute to symptom changes.

GLP1Place previously covered knee-related retatrutide evidence in its article on retatrutide and knee osteoarthritis research. TRIUMPH-1 adds evidence from a large phase 3 program and a prespecified subgroup. It should not be read as proof of a separate osteoarthritis indication.

What the sleep apnea subgroup found

Obstructive sleep apnea occurs when the upper airway repeatedly narrows or closes during sleep. Obesity is an important risk factor. In TRIUMPH-1, researchers used sleep testing to measure the apnea-hypopnea index, or AHI.

Under the hybrid-treatment estimand, AHI changed by -22.9 events per hour with 4 mg retatrutide, -34.3 events per hour with 9 mg, and -31.7 events per hour with 12 mg. The placebo group improved by 9.9 events per hour. The differences versus placebo were -24.4 events per hour for 9 mg and -21.9 events per hour for 12 mg, both with P values below 0.001.

The intention-to-treat findings were similar. AHI changed by -22.8, -34.3, and -32.1 events per hour in the retatrutide groups, compared with -9.6 events per hour with placebo. The estimated differences versus placebo were -24.7 and -22.5 events per hour for the 9 mg and 12 mg groups.

The subgroup findings show improvement in a measured breathing-event outcome. They do not establish lower rates of heart attack, stroke, motor-vehicle accidents, mortality, or every other long-term outcome associated with sleep apnea. They also do not answer questions about changes to other sleep-apnea care. Those clinical decisions are separate from this obesity trial’s results.

Retatrutide side effects and safety limits

Gastrointestinal adverse events were the most common safety findings reported in TRIUMPH-1. This broad pattern is consistent with incretin-based medicines, although the type, frequency, and severity of events can vary by molecule, dose, dose-escalation schedule, and study population.

The published report should be consulted for the complete safety tables, including specific adverse events, serious events, discontinuations, and laboratory findings. The article’s PubMed record provides an additional indexed source for the study: TRIUMPH-1 on PubMed.

Several cautions matter when interpreting the safety data:

• Large phase 3 trials are better than small early studies at identifying common adverse events.
• A 2,339-participant trial may still be too small to define very rare risks.
• An 80-week study cannot fully describe effects that may emerge after years of exposure.
• Clinical trials use inclusion and exclusion criteria, so findings may not apply equally to every population.
• The trial was funded by the developer, making independent review and regulatory assessment important.

Retatrutide is not an approved medicine. The doses, schedule, and duration in this article are reported study details, not instructions or recommendations for use.

How TRIUMPH-1 extends earlier retatrutide research

Earlier retatrutide studies suggested that the triple-agonist approach could produce substantial weight reduction over shorter periods. TRIUMPH-1 adds a larger phase 3 dataset, 80-week follow-up, and prespecified assessments of obesity-related conditions.

This progression matters in drug development. Early trials often focus on dose exploration, pharmacology, short-term tolerability, and initial efficacy signals. A phase 3 trial can provide a more stable estimate of average outcomes in a larger population. Even so, a positive phase 3 trial is not the final word on long-term benefit-risk balance.

For background on the three-receptor design, see GLP1Place’s retatrutide triple-agonist research overview. TRIUMPH-1 is a material clinical update to that background because it reports peer-reviewed phase 3 outcomes rather than only mechanism or earlier-stage evidence.

Does TRIUMPH-1 prove retatrutide is better than semaglutide or tirzepatide?

No. TRIUMPH-1 compared retatrutide with placebo, not with semaglutide, tirzepatide, or another active obesity medicine. It shows that retatrutide outperformed placebo under the study conditions. It cannot establish superiority over another medicine.

Cross-trial comparisons can mislead because studies differ in population, treatment duration, dose escalation, counseling, adherence, discontinuation patterns, and statistical methods. Studies in people with diabetes also cannot be assumed to produce the same results as studies in people without diabetes.

Randomized head-to-head trials would provide more useful comparative evidence. Such research would need similar populations, balanced study designs, and enough follow-up to assess both weight maintenance and safety. Dedicated cardiovascular-outcomes research would also be needed to determine whether weight reduction translates into fewer major cardiovascular events.

What the results mean for obesity-drug research

TRIUMPH-1 strengthens the evidence base for medicines that act on more than one metabolic receptor. In this study, a GLP-1, GIP, and glucagon receptor agonist produced large average weight reductions and improved selected obesity-related measures compared with placebo.

The trial also reflects a broader direction in obesity research. Weight is important, but it is not the only outcome that matters. Researchers increasingly assess conditions linked with obesity, including sleep apnea, mobility limitations, joint symptoms, blood pressure, glucose measures, liver disease, and physical function. A broad evidence package can clarify both potential benefits and important limitations.

Important unanswered questions remain:

1. Whether weight changes are maintained after treatment ends.
2. Whether lean mass and bone health are preserved over longer follow-up.
3. Whether gastrointestinal adverse events limit long-term persistence.
4. Whether retatrutide reduces major cardiovascular events.
5. Whether findings generalize across different ages, ethnic groups, diabetes status, and comorbidity profiles.
6. How retatrutide compares directly with semaglutide, tirzepatide, and future medicines.

Regulatory status and research boundaries

Retatrutide remains investigational as of October 3, 2026. A positive phase 3 publication does not equal FDA approval. Regulatory review considers the complete clinical program, manufacturing controls, product quality, proposed labeling, safety monitoring, and the overall benefit-risk profile.

A clinical trial evaluates a defined investigational product under controlled conditions. Its findings should not be treated as evidence about unverified products outside a trial setting. The trial report also does not provide a basis for self-directed use.

Readers seeking general background on the regulatory meaning of research-use-only products can review GLP1Place’s educational article on research peptides and the regulatory framework. That background does not alter retatrutide’s investigational status.

Researcher takeaways

The central TRIUMPH-1 finding is clear: in adults with obesity or overweight without diabetes, retatrutide produced large, dose-related average weight reductions over 80 weeks and improved measured knee-pain and sleep-apnea outcomes compared with placebo.

The limits are also clear. The study was placebo-controlled, not head-to-head. It was funded by the molecule’s developer. Gastrointestinal adverse events were common. It was not designed to settle every long-term safety question or prove cardiovascular benefit. Retatrutide is also not approved for routine treatment.

For obesity research, the report marks an important phase 3 milestone. The next evidence questions involve durability, tolerability, broad applicability, long-term safety, and whether triple-receptor pharmacology offers a meaningful advantage when tested directly against other approaches.

Frequently asked questions

What did the retatrutide phase 3 obesity trial find?

In TRIUMPH-1, adults with obesity or overweight without diabetes received retatrutide or placebo for 80 weeks. Average weight change was 17.6% with 4 mg, 23.7% with 9 mg, and 25.0% with 12 mg, compared with 3.9% with placebo under the treatment-regimen analysis.

What is retatrutide?

Retatrutide, also called LY3437943, is an investigational triple hormone receptor agonist. It activates the GLP-1, GIP, and glucagon receptors in one molecule. It is not an FDA-approved medicine as of October 3, 2026.

Did retatrutide improve knee osteoarthritis pain?

Yes. In the TRIUMPH-1 knee osteoarthritis subgroup, retatrutide reduced WOMAC pain scores more than placebo after 80 weeks. The statistically significant finding does not prove that retatrutide directly treats joint disease independently of weight loss.

Did retatrutide improve obstructive sleep apnea?

Yes. In the obstructive sleep apnea subgroup, retatrutide reduced the apnea-hypopnea index more than placebo. The study measured breathing events and did not assess every long-term outcome associated with sleep apnea.

What were the most common retatrutide side effects?

Gastrointestinal adverse events were the most common side effects reported in TRIUMPH-1. The study adds important safety information, but it was not large or long enough to resolve every uncommon or delayed risk.

Is retatrutide approved for weight loss?

No. Retatrutide remains investigational as of October 3, 2026. Phase 3 findings are important evidence, but approval requires regulatory review of the full development program, manufacturing information, and benefit-risk profile.